Home > Riviste > Minerva Anestesiologica > Fascicoli precedenti > Minerva Anestesiologica 2012 March;78(3) > Minerva Anestesiologica 2012 March;78(3):330-5



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca




ORIGINAL ARTICLES   Free accessfree

Minerva Anestesiologica 2012 March;78(3):330-5


lingua: Inglese

Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices

Pappalardo F. 1, Scandroglio A. M. 1, Potapov E. 2, Stepanenko A. 2, Maj G. 1, Krabatsch T. 2, Zangrillo A. 1, Koster A. 3, Hetzer R. 2

1 Department of Cardiothoracic and Vascular Anesthesia and Intensive Care, Vita-Salute University, San Raffaele Hospital, Milan, Italy; 2 Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum, Berlin, Germany; 3 Heart and Diabetes Center, Bad Oeynhausen, Germany


BACKGROUND: Patients receiving implantation of ventricular assist devices (VAD) suffer a high incidence of heparin induced thrombocytopenia (HIT); the occurrence of this condition is associated with increased complications and worse outcomes. We report our experience in the management of patients who were diagnosed with HIT either before (HITpre) or after (HITpost) implantation of VAD with argatroban, a direct thrombin inhibitor.
METHODS: This retrospective analysis assessed data of VAD patients diagnosed with HIT at Deutsches Herzzentrum Berlin between November 2005 and April 2009. Argatroban dose requirements, anticoagulation efficacy and adverse events (death, thromboembolism, bleeding) were recorded. Procedural success (discharge from the hospital, heart transplantation, or recovery of the failing heart) was also assessed.
RESULTS: Twenty-seven patients were identified (11 HITpre, 16 HITpost). Argatroban was effective in obtaining adequate anticoagulation with a reduced dose regimen (0.02-0.42 mcg/Kg/min starting dose; 0.02-1.5 mcg/Kg/min maintenance dose). We noted 5 thromboembolic complications (18%), 6 cases of major bleeding (22%) and 5 deaths (18%), all cause composite adverse end point occurring in 40% of patients. Procedural success was obtained in 81% of patients (92% HITpre, 69% HITpost). As compared to historical controls of patients treated with lepirudin in the period 2000-2005, results were significantly improved.
CONCLUSION: Argatroban anticoagulation is feasible in patients with HIT after VAD implantation, without increasing bleeding risk. Its impact in terms of survival should be reviewed also in the light of the technological improvements of assist devices.

inizio pagina